Patients with chronic obstructive pulmonary disease (COPD) frequently experience nocturnal hypoxemia, which severely impairs sleep quality and exacerbates daytime symptoms. In-depth analysis of the intricate mechanisms causing nighttime oxygen desaturation in COPD and developing effective countermeasures are crucial unmet needs in current respiratory medicine.
Why COPD Patients Develop Nocturnal Hypoxemia
Isolated Nocturnal Hypoxemia
Isolated nocturnal hypoxemia refers to oxygen desaturation occurring mainly during sleep in COPD patients without overt sleep-disordered breathing. The repetitive drops in blood oxygen levels are typically induced by the following pathological changes at night:
- Decreased central respiratory drive and chest wall muscle activity. The automatic control of breathing relies on metabolic signals like pO2, pCO2, and pH detected by central and peripheral chemoreceptors. At night, the wakefulness drive promoting ventilation subsides. Meanwhile, COPD patients already have blunted chemosensitivity. These compounding factors lead to reduced respiratory center output and weakened contraction of inspiratory muscles including the diaphragm.
- Increased airway resistance. Bronchial smooth muscle tone regulating airway caliber follows circadian rhythm and cholinergic modulation. The parasympathetic nervous system exhibits heightened activity during non-REM sleep. The synergistic effects cause pronounced bronchoconstriction and greater airflow resistance overnight.
- Ventilation-perfusion mismatch. Because of air trapping, some lung units are poorly ventilated relative to perfusion. Sleep further aggravates V/Q imbalance as ventilation declines disproportionately more than cardiac output. This results in a low ventilation-high perfusion ratio in certain pulmonary areas, impeding optimal gas exchange. The end outcome is oxygen diffusion limitation across the alveolar-capillary membrane and reduced blood oxygenation.
Frequent Overlap with Other Sleep-disordered Breathing
COPD patients frequently have coexisting sleep-related breathing disorders like obstructive sleep apnea-hypopnea syndrome (OSAHS), central sleep apnea syndrome, and obesity hypoventilation syndrome on top of baseline airflow obstruction. These superimposed conditions predispose to worse oxygen desaturation spells:
- The most common overlap syndrome involves COPD and OSAHS, termed overlap syndrome (OCOS). Population-based studies estimate over 50% of COPD patients also suffer from OSAHS but this is largely underdiagnosed. The prevalence of OCOS rises with the increasing severity of COPD.
- OCOS patients experience more severe, prolonged bouts of oxyhemoglobin desaturation compared to either condition alone. The repetitive hypoxemia and sleep fragmentation lead to greater oxidative stress, systemic inflammation, polycythemia, and hypercoagulation - increasing risks of pulmonary hypertension, arrhythmias, stroke, and acute exacerbations. OCOS also accelerates lung function decline and all-cause mortality if left untreated.
Pathogenesis of OCOS
The occurrence of OCOS has multifactorial underpinnings:
- Narrowed, collapsible upper airway. COPD per se does not obstruct the upper airway. However, these patients have heightened loop gain of chemical feedback control and diminished upper airway dilator muscle responsiveness during sleep. This raises the arousal threshold for airway reopening and predisposes to pharyngeal collapse.
- Muscle relaxation triggering events. As upper airway dilators like the genioglossus relax with non-REM sleep onset, the critical closing pressure is more easily exceeded, resulting in airway occlusion and cessation of airflow. The interaction between anatomical and neurological factors explains why obstructive events cluster during rapid eye movement sleep.
- Blunted respiratory drive. Hyperinflation and intrinsic PEEP impose increased mechanical load on COPD patients, requiring higher neural respiratory drive to overcome. Compounding the elevated plant gain, the reduced controller gain or central ventilatory motor output further permits respiratory events.
- Ventilation-perfusion mismatch. In addition to V/Q abnormalities in COPD itself, apneic episodes create severe V/Q inequality via oxygen consumption and carbon dioxide retention. Post-event hyperpnea also worsens V/Q mismatch by altering regional blood flow distribution. These ultimately culminate in profound desaturation.
Other Sleep-related Breathing Disorders
On top of OSAHS, COPD patients can present other forms of sleep-disordered breathing including sleep-related hypoventilation and increased respiratory event index. The spectrum encompasses obstructive hypoventilation with elevated PACO2, central apneas, and hypopneas from chemoreflex dysfunction or cardiac insufficiency, as well as periodic breathing cycles. Screening is warranted as multi-faceted respiratory abnormalities frequently co-exist.
When Is Nocturnal Oxygen Therapy Indicated
Meeting Standard Criteria for Home Oxygen Therapy
Long-term oxygen treatment aims to:
- Correct resting and nocturnal hypoxemia
- Stabilize pulmonary hemodynamics
- Improve survival
The standard eligibility criteria are:
- Arterial PaO2 ≤ 55 mmHg or SpO2 ≤ 88% in stable condition, with or without hypercapnia - occurring at least twice weekly over 3 weeks. This is regardless of whether symptoms are present.
- PaO2 between 55-60 mmHg plus signs of congestive heart failure and/or hematologic sequelae of chronic hypoxemia - pulmonary hypertension documented on echocardiography, peripheral edema indicating right heart failure, or polycythemia with hematocrit >55%.
Controversy Regarding Borderline Nocturnal Desaturation
Current guidelines do not provide clear recommendations on managing COPD patients with episodic overnight oxygen dips not meeting the aforesaid thresholds. Since the appropriateness of oxygen therapy hinges on its risk-benefit ratio, there are a few considerations in this "grey zone":
- Absolute indications - PaO2 <50 mmHg for ≥30% of sleep time OR ≥10 mins with SpO2 <80% signifies severe hypoxemia. Oxygen should be supplied based on the dangers of prolonged, profound deoxygenation.
- No indications - Studies on COPD patients having only modest desaturation during rapid eye movement sleep showed nocturnal oxygen neither reduced pulmonary arterial pressures nor improved survival. If SpO2 remains >90% most of the time, oxygen therapy confers little advantage.
- Individualized decision - For moderate severity (SpO2 often 80-90%), the potential benefits of minimizing hypoxemia's adverse effects need to be weighed against oxygen toxicity concerns with liberal supplying. Adjunctive measurements like pulmonary pressures, hypercapnia and overnight oximetry help guide treatment.
Noninvasive positive pressure ventilation (NPPV) offloads respiratory muscles and enhances alveolar ventilation. By improving gas exchange, it alleviates both hypoxemia and hypercapnia. COPD patients may benefit in the following clinical contexts:
Acute or Acute-on-chronic Respiratory Failure
Exacerbations represent potentially life-threatening events. Trials consistently demonstrate that NPPV, compared to standard therapy alone, significantly decreases intubation and mortality rates by:
- Unloading excessively strained respiratory muscles
- Reexpanding collapsed alveoli and recruiting functionally closed lung units
- Reversing V/Q mismatch - improving oxygenation and correcting CO2 retention
Thus, NPPV is strongly recommended as an adjunct to treat acidotic exacerbations not responding adequately to bronchodilators, corticosteroids, and controlled oxygen
Chronic Stable Hypercapnia
Long-term NPPV is clinically efficacious for COPD patients having:
- Severe daytime hypercapnia - PaCO2 ≥ 55 mmHg
- Nocturnal alveolar hypoventilation - rise in PaCO2 ≥ 10 mmHg relative to daytime
- Severe dyspnea despite optimal therapy
It lessens dyspnea, boosts muscle endurance, and enhances health-related quality of life. Through offloading ventilatory demands and restituting diurnal PaCO2 fluctuation, NPPV stabilizes or slows respiratory decline.
Overlap Syndrome (OCOS)
NPPV concurrently addresses dual airway obstruction and nocturnal hypoventilation in OCOS. Tailored hybrid modes (e.g. AVAPS) dynamically support ventilation needed for correcting apneas/hypopneas while ensuring adequate CO2 elimination. This synergistically combats the repetitive oxygen desaturation, sleep disruption, and systemic effects beyond first-line OSAHS therapy.
OSAHS- vs COPD-predominant OCOS
Therapy principles hinge on the primary driver of respiratory events:
- For OSAHS-predominant OCOS, NPPV mainly treats the obstructive component while supplemental oxygen manages hypoxemia.
- Conversely, oxygen and NPPV primarily target hypoventilation if COPD predominates mildly symptomatic OSAHS.
- With co-dominant moderate-severe OSAHS and COPD, intensive combination treatment is warranted for optimal outcomes.
Polysomnography for Evaluating Sleep Disorders
Polysomnography using multi-parameter recordings remains the gold standard diagnostic test for sleep-disordered breathing. It frequently uncovers occult problems and provides guidance on therapeutic necessity in COPD. Typical monitored parameters include:
Patterns of Ventilation
- Nasal and oral airflow - capturing obstructive or central events, hypopneas
- Chest and abdominal respiratory efforts - identifying central apneas
- Pulse oximetry - measuring intensity and duration of oxygen desaturation
- Transcutaneous or end-tidal CO2 monitoring - quantifying hypo/hypercapnia
Sleep Stage & Continuity
- Electrooculogram (EOG) - signaling rapid eye movement sleep onset
- Electroencephalogram (EEG) - distinguishing non-REM sleep stages
- Electromyogram (EMG) - depicting skeletal muscle tone changes
This tracks sleep architecture, continuity, and the impact of respiratory events on arousal/awakening.
Cardiac Rhythm & Rate
Continuous ECG monitoring additionally determines if arrhythmias co-exist or heart rate variability alters with sleep-disordered breathing.
By holistically collecting multidimensional data, polysomnography facilitates identifying the complete range of sleep-related respiratory problems plaguing COPD patients. It thereby enables targeted, patient-specific early interventions instead of one-size-fits-all therapy.
Home Oxygen Concentrators for COPD
Long-term oxygen treatment improves survival in eligible COPD patients. Concentrators provide cheaper, convenient stationary sources for patients requiring high-flow supplemental oxygen.
Oxygen concentrators utilize pressure swing adsorption to selectively absorb nitrogen from room air using zeolite molecular sieves. This elevates the oxygen concentration up to 95% for release to users through a nasal cannula. Flow rate and boluses can be customized to your needs. Concentrators spare patients from frequent cylinder delivery and are preferred for round-the-clock oxygen.
The choice depends on flow rate, weight, and noise level suited for the patient's oxygen needs, mobility, and home environment. Units supplying up to 10 liters per minute (LPM) with options for double cannulas are preferable for very severe COPD.
- Severe baseline hypoxemia - PaO2 ≤55 mmHg or SpO2 ≤88%
- Exertional/nocturnal desaturation is only partially relieved by bronchodilators
- Frequent oxygen desaturation hampering activities of daily living
- Signs of cor pulmonale from chronic hypoxemic vasoconstriction
Usage & Maintenance
Patients should undergo repeat Oximetry on supra-maximal oxygen doses to readjust devices for optimal alleviation of hypoxemia without CO2 retention. Proper placement and interface fitting enhances comfort and compliance. Routine servicing and cleaning maintain the purity of oxygen delivery. Adjunct humidification prevents mucosal drying. Users ought to stay cognizant of fire safety and tripping hazards from tubing.
COPD patients often develop nocturnal oxygen desaturation owing to complex pathways spanning respiratory control instability, mechanic loading, chemosensitivity, and sleep changes. Thorough evaluation by polysomnography helps diagnose co-existing sleep disorders frequently missed and enables targeted interventions. Concentrator-based home oxygen therapy effectively relieves chronic hypoxemia while noninvasive ventilation supports ventilation and gas exchange in suitable patients, altogether improving quality of life.
- Working Principle of Portable Oxygen Concentrator - Lovego Medical
- How To Solve Beeping Alarms on Your Oxygen Concentrator - Lovego Medical
- Select the Right Portable Oxygen Concentrator for Active Lifestyles - Lovego Medical
- Choosing Your idea POC: Pulse vs. Continuous Flow - Lovego Medical
- How to Choose a Right Device - Lovego Medical